Therapeutic Action
Bronchodilator, anticholinergic drug
PDF page 175
Loading InternPractice…
Drug reference
Bronchodilator, anticholinergic drug
PDF page 175
Severe asthma attack, in combination with salbutamol
PDF page 175
May cause: throat irritation, headache, cough, vomiting; anticholinergic effects: dryness of the mouth, constipation, dilation of the pupils, blurred vision, urinary retention, tachycardia. Administer with caution to older patients and patients with closed-angle glaucoma, urethro- prostatic disorders, urinary retention. Avoid or monitor combination with drugs known to have anticholinergic effects: tricyclic antidepressants (e.g. amitriptyline), first generation H-1 antihistamines (e.g. hydroxyzine, promethazine), biperiden, antispasmodics (e.g. atropine, hyoscine butylbromide), antipsychotics (e.g. chlorpromazine, haloperidol), etc. (increased risk of adverse effects). Pregnancy: no contra-indication Breast-feeding: no contra-indication
PDF page 175
Solution for inhalation, in unit dose vial of 0.25 mg in 1 ml (0.25 mg/ml) and 0.5 mg in 2 ml (0.25 mg/ml), to be administered via a nebuliser
PDF page 175
Child under 5 years: 0.25 mg (1 ml) per nebulisation every 20 minutes for the first hour Child 5 years and over and adult: 0.5 mg (2 ml) per nebulisation every 20 minutes for the first hour
PDF page 175
Volumes of nebuliser solution to be administered are insufficient to obtain efficient nebulisation in most nebulisers: add ipratropium to salbutamol and then 0.9% sodium chloride to obtain a total volume of 5 ml in the reservoir of the nebuliser. Stop the nebulisation when the reservoir is empty (after around 10 to 15 minutes).
PDF pages 175, 176
– Below 25 °C
PDF page 176
0.25 mg (1 ml) per nebulisation every 20 minutes for the first hour
PDF page 175
0.5 mg (2 ml) per nebulisation every 20 minutes for the first hour
PDF page 175